Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short‐Chain Fatty Acids
The Laryngoscope · 2025
DOI: 10.1002/lary.32414 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Rikako Gozawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan. Hauptthemen laut MEDLINE: Sinusitis, Rhinitis, Fatty Acids, Volatile, Eosinophilia. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MSD Life Science Foundation, Public Interest Incorporated Foundation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objective
Epithelial cell‐derived cytokines play a key role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNPs). Short‐chain fatty acids (SCFAs) are carboxylic acids with 1–6 carbon atoms that are produced by the microbiota, which play a significant role in inflammation. We evaluated the potential role of SCFAs in eosinophilic chronic rhinosinusitis (ECRS).
Methods
Gene expression levels of G protein‐coupled receptor 41/free fatty acid receptor 3 (GPR41/FFAR3), GPR43/FFAR2, thymic stromal lymphopoietin (TSLP), interleukin (IL)‐25, and IL‐33 in nasal polyp (NP) tissues were analyzed using quantitative real‐time polymerase chain reaction. Primary normal human bronchial epithelial (NHBE) cells were stimulated with polyinosinic‐polycytidylic acid (poly(I:C)) in the presence or absence of SCFAs, and TSLP levels were measured. Immunohistochemical analysis was conducted to evaluate GPR41 expression in eosinophils and the Eol‐1 human eosinophilic leukemic cell line (Eol‐1 cells). The viability of Eol‐1 cells treated with propionic acid was also assessed.
Results
Both GPR41 and GPR43 mRNA expression was significantly higher in ECRS‐NPs than in non‐ECRS‐NPs. The level of TSLP mRNA expression was also significantly elevated in ECRS‐NPs that correlated with eosinophil counts in NP tissues. Although poly(I:C) stimulation induced TSLP expression in NHBE cells, acetic acid, propionic acid, and butyric acid significantly suppressed TSLP expression in a concentration‐dependent manner. GPR43 was expressed in eosinophils from NP tissues and Eol‐1 cells. 1 mM propionic acid significantly suppressed Eol‐1 cell survival.
Conclusions
SCFAs, particularly propionic acid, may be effective in treating ECRS by suppressing TSLP expression and eosinophils. Level of Evidence NA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
ORCID-Profile: Rikako Gozawa, Naoto Adachi, Shigeharu Fujieda
Förderung
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Naito Foundation
Zitieren
APA
Gozawa, R., Imoto, Y., Sonoda, Y., Maegawa, A., Shimizu, A., Kidoguchi, M., Koyama, K., Adachi, N., Morikawa, T., Miyazaki, Y., Saito, K., Sakashita, M., & Fujieda, S. (2025). Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short‐Chain Fatty Acids. The Laryngoscope. https://doi.org/10.1002/lary.32414
Vancouver
Gozawa R, Imoto Y, Sonoda Y, Maegawa A, Shimizu A, Kidoguchi M, et al. Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short‐Chain Fatty Acids. The Laryngoscope. 2025. doi:10.1002/lary.32414
BibTeX
@article{Gozawa2025,
author = {Gozawa, Rikako and Imoto, Yoshimasa and Sonoda, Yuki and Maegawa, Ayako and Shimizu, Anna and Kidoguchi, Masanori and Koyama, Keisuke and Adachi, Naoto and Morikawa, Taiyo and Miyazaki, Yuto and Saito, Kyoko and Sakashita, Masafumi and Fujieda, Shigeharu},
title = {Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short‐Chain Fatty Acids},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32414}
}
EUVIMED